Huanxin Medical Completes Series B Funding to Advance Structural Heart and Vascular Intervention Solutions

CardioCycle Technology (Suzhou) Co., Ltd. (referred to as "CardioCycle") announced the completion of its Series B financing. This round of financing will help CardioCycle accelerate product development and market expansion, further solidifying its leading position in the interventional medical device field.

CardioCycle Technology (Suzhou) Co., Ltd. was established in 2020 as an innovative medical device developer specializing in the research and development of interventional medical devices. The company is committed to innovation in the research, manufacturing, and related technical fields of interventional medical devices. Its product portfolio includes structural heart disease and surgical accessories, as well as interventional vascular access products, forming a comprehensive range of solutions in the fields of structural heart disease and vascular intervention in China.

CardioCycle was co-founded by core engineers of medical devices, clinical experts, and capital parties. The company focuses on providing one-stop solutions for precise interventional treatments, covering cardiac interventions and pan-vascular interventions. Production and R&D centers have been established in Suzhou Biobay, China, and Galway GMIT, Ireland. The company is committed to becoming an interventional medical solutions provider that deeply cultivates research and manufacturing, serving patients and contributing globally.

CardioCycle Technology (Suzhou) Co., Ltd.'s core product lines focus on the cardiovascular and peripheral vascular intervention fields, mainly divided into the following three major categories:

1. Cardiovascular Interventional Devices: OccluFar SealFar® Balloon Occlusion Microcatheter, a pioneering product in China, features an integrated "delivery + occlusion" function. It is suitable for tumor interventional treatments (such as TACE procedures for liver cancer) and is one of the top three products of its kind globally, filling a gap in the Chinese market. Corsharp BoYu® Atrial Septal Puncture System, used for atrial septal puncture operations during cardiac interventional surgeries, has been approved for marketing. Corbend BoXiang® Steerable Sheath System provides precise catheter guidance and support, adaptable to complex vascular pathways. RadialFar RaoYou® / MicroFar CongYou® Microcatheters are designed for transradial and transfemoral interventional approaches, respectively. SteerFar QuYou® Steerable Microcatheter enhances intraoperative maneuverability.
2. Peripheral Vascular Intervention Devices: AccuFar Benyou™ Micro Guidewire, approved for marketing in November 2024. It includes three diameter specifications of 0.014"/0.016"/0.018" and 21 length models, featuring excellent torque control, strong tip compliance, and a hydrophilic coating along the entire body to reduce friction.

Features. Corpassing Bohuai® Catheter Sheath Set, a core tool for establishing vascular access. Corflow Bohan® Balloon Dilatation Catheter, used for vascular angioplasty.

1. Implantable Devices: Polyvinyl Alcohol Embolic Microspheres, used for tumor vascular embolization therapy.